Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer HealthCare LLC

Division of Bayer AG
www.healthcare.bayer.com

Latest From Bayer HealthCare LLC

Bayer's Aleve 'Proven Better' Than Tylenol Claims Fail In J&J Challenge At NAD

Bayer appeals to National Advertising Review Board over NAD’s finding the firm didn't support claims its Aleve OTC provides superior pain-relief to J&J’s Tylenol. It says NAD misunderstands scientific data and it will argue pain studies it submitted were methodologically sound and pain-relief statements were not overly broad.
OTC Drugs Ad Complaints

Bayer Supports Claritin-D Indications Claim, Not Superiority Over GSK's Flonase

Bayer supports making an “8 versus 6 FDA-approved indications” comparison with GSK's Flonase ,but it fails when suggesting Flonase doesn't relieve "sinus congestion and pressure” and “itchy throat” based only on GSK's competing product not receiving FDA approval for those indications, says NAD.

OTC Drugs Advertising, Marketing & Sales

Regular Aspirin Use To Prevent Cardiovascular Events Not Advisable For Most Patients – ACC/AHA Guidelines

Aspirin should be used very selectively in the primary prevention of artherosclerotic cardiovascular disease, according to new guidelines from the American College of Cardiology and American Heart Association. While certain higher-risk adults may benefit from regular, preventative aspirin use, those over the age of 70, and any at increased risk of bleeding, should explore lifestyle changes, the groups say.

Health Cardiovascular

Orphan Drug Makers Get Selected Tax Breaks As China Turns To Access

Following anticancer drugs, rare disease treatments become the latest products in China’s to get value added tax reductions. Orphan drug makers can breath easier, but much more is needed, industry insiders say.

China Rare Diseases
See All

Company Information

UsernamePublicRestriction

Register